SB 278: Federal 340-B Drug Pricing Program; impacts within the Commonwealth.

Official summary

Abstract published by the legislature (via Open States). Text as published by the legislature; reproduced verbatim.

Drug manufacturers; 340B Drug Pricing Program; work group; report. Directs the Secretary of Health and Human Resources to convene a work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth, with emphasis on governance, transparency, and the availability of pharmacy services in rural and underserved areas. The bill requires the work group to submit a report on its findings and recommendations to the Chairs of the Senate Committees on Finance and Appropriations and Education and Health and the House Committees on Appropriations and Health and Human Services by November 1, 2026.

Sponsors

Sponsors by party (alphabetical): Democratic 6

“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.

Recent official actions

1. April 13, 2026Approved by Governor-Chapter 887 (effective 7/1/2026)
2. March 14, 2026Governor's Action Deadline 11:59 p.m., April 13, 2026
3. March 14, 2026Enrolled Bill communicated to Governor on March 14, 2026
4. March 12, 2026Signed by Speaker
5. March 11, 2026Signed by President
6. March 11, 2026Fiscal Impact Statement from Department of Planning and Budget (SB278)
7. March 11, 2026Bill text as passed Senate and House (SB278ER)
8. March 11, 2026Enrolled
9. March 5, 2026House amendments agreed to by Senate (39-Y 0-N 0-A)
10. March 3, 2026Passed House with amendments (97-Y 0-N 0-A)
11. March 3, 2026Engrossed by House as amended
12. March 3, 2026committee amendments agreed to

Showing 12 most recent of 40 actions. Full history